Mechanism of nitrogen metabolism-related parameters and enzyme activities in the pathophysiology of autism

Journal of Neurodevelopmental Disorders

Volumn 4, Issue 1, 2012, Pages 1-11

  Abu Shmais, Ghada A ^a   Al Ayadhi, Laila Y ^b,c   Al Dbass, Abeer M ^a   El Ansary, Afaf K ^a,b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Autism Research and Treatment Center   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 5' NUCLEOTIDASE; ADENOSINE DEAMINASE; CREATINE; GLUTAMIC ACID; GLUTAMINE; NITROGEN;

AMINO ACID BLOOD LEVEL; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NITROGEN METABOLISM; PARAMETERS; PATHOPHYSIOLOGY;

EID: 84861840994     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/1866-1955-4-4     Document Type: Article

References (60)

1. Centers for Disease Control and Prevention (CDC): Prevalence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network-14 Sites, United States, 2002. MMWR Surveill Summ 2007, 56:12-28.
2. Lord C, Cook EH, Leventhal BL, Amaral DG: Autism Spectrum disorders. Neuron 2000, 28:355-363.
3. Amaral DG: The promise and the pitfalls of autism research, an introductory note for new autism researchers. Brain Res 2011, 1380:3-9.
4. Geier MR, Geier DA: Autism spectrum disorder-associated biomarkers for case evaluation and management by clinical geneticists. Expert Rev Mol Diagn 2008, 8:671-674.
5. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L: Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem 2009, 42:1032-1040.
6. Al-Mosalem O, El-Ansary A, Attas O, Al-Ayadhi L: Metabolic biomarkers related to energy metabolism in Saudi autistic children. Clin Biochem 2009, 42:949-957.
7. Nelson DL, Cox MM: Lehninger Principles of Biochemistry New York: Worth Publishers; 2000.
8. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA: Nacetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007, 81:89-131.
9. Boison D: Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 2008, 8:2-7.
10. Siegel GJ, Agranoff BW, Fisher SK, Albers RW, Uhler MD: Basic Neurochemistry: Molecular, Cellular, and Medical Aspects Philadelphia: Lippincott Williams & Wilkins; 1999.
11. Barsotti C, Ipata PL: Metabolic regulation of ATP breakdown and of adenosine production in rat brain extracts. Int J Biochem Cell Biol 2004, 36:2214-2225.
12. Romanowska M, Ostrowska M, Komoszyński MA: Adenosine Ectodeaminase (ecto-ADA) from porcine cerebral cortex synaptic membrane. Brain Res 2007, 1156:1-8.
13. Guix FX, Uribesalgo I, Coma M, Muñoz FJ: The Physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005, 76:126-152.
14. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR: Functions and effects of creatine in the central nervous system. Brain Res Bull 2008, 76:329-343.
15. Bachmann C, Braissant O, Villard AM, Boulat O, Henry H: Ammonia toxicity to the brain and creatine. Mol Genet Metab 2004, 81:52-57.
16. Ryu H, Rosas HD, Hersch SM, Ferrante RJ: The therapeutic role of creatine in Huntington's disease. Pharmacol Ther 2005, 108:193-207.
17. World Medical Association Declaration of Helsinki (WMA), Ethical Principles for Medical Research Involving Human Subjects., Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at: http://www.wma.net/en/30publications/10policies/b3/. Accessed September 20, 2007.
18. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994, 24:659-685.
19. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schoper E: Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 1989, 19:185-212.
20. Skuse D, Warrington R, Bishop D, Chowdhury U, Lau J, Mandy W, Place M: The Developmental, Dimensional and Diagnostic Interview (3di): a novel computerized assessment for autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2004, 43:548-558.
21. Bertrand A, Buret J: A one-step determination of serum 5'-nucleotidase using a centrifugal analyzer. Clin Chim Acta 1982, 119:275-284.
22. Kalkan A, Bulut V, Erel O, Avci S, Bingol NK: Adenosine Deaminase and guanosine deaminase activities in sera of patients with viral hepatitis. Mem Inst Oswaldo Cruz 1999, 94:383-386.
23. Schmidt E, Schmidt FW: Glutamate dehydrogenase. Methods of Enzymatic Analysis. 3 edition. Weinheim: Verlag Chemie; 1983, 216-227.
24. Mondzac A, Ehrlich GE, Seegmiller JE: An enzymatic determination of ammonia in biological fluids. J Lab Cli Med 1965, 66:526-531
25. Patton CJ, Crouch SR: Spectrophotometric and kinetics investigation of the Berthelot reaction for the determination of ammonia. Anal Chem 1977, 49:464-469.
26. Riksen NP, Van Ginneken EE, Van den Broek PH, Smits P, Rongen GA: In vivo evidence against a role for adenosine in the exercise pressor reflex in humans. J Appl Physiol 2005, 99:522-527.
27. Caretti A, Bianciardi P, Ronchi R, Fantacci M, Guazzi M, Samaja M: Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1 signaling. Exp Biol Med (Maywood) 2008, 233:1222-1230.
28. Suresh Babu VS, Shareef MM, Pavan Kumar Shetty A, Taranath Shetty K: HPLC method for amino acids profile in biological fluids and inborn metabolic disorders of aminoacidopathies. Indian J Clin Biochem 2002, 17(2):7-26.
29. Bradford M: A rapid and sensitive method for the quantification of micrograms quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976, 76:248-254.
30. Tarnopolsky MA, Beal MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001, 49:561-574.
31. Butterfield DA, Kanski J: Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 2001, 122:945-962.
32. Wyss W, Schulze A: Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience 2002, 112:243-260.
33. Kara B, Caliskan M, Anik Y, Gokcay G: X-linked creatine transport deficiency in five patients with behavioral abnormalities, mental retardation and/or epilepsy. Proceedings of European Paediatric Neurology Society Congress, 9th EPNS Congress, Cavtat, Croatia, 23 February 2011. Available (poster) at: http://www.sciencedirect.com/science/article/pii/S1090379811703476.
34. Stockler S, Marescau B, De Deyn PP, Trijbels JM, Hanefeld F: Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis. Metabolism 1997, 46:1189-1193.
35. Kayser MA: Inherited metabolic diseases in neurodevelopmental and neurobehavioral disorders. Semin Pediatr Neurol 2008, 15:127-131.
36. Battini R, Leuzzi V, Carducci C, Tosetti M, Bianchi MC, Item CB, Stöckler- Ipsiroglu S, Cioni G: Creatine depletion in a new case with AGAT deficiency: clinical and genetic study in a large pedigree. Mol Genet Metab 2002, 77:326-331.
37. Sogut S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Akyol O: Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003, 331:111-117.
38. Al-Yafee YA, Al-Ayadhi LY, Haq SH, El-Ansary AK: Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia. BMC Neurology 2011, 11:139.
39. Donofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J: Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest 1978, 62:884-887.
40. Lizuka H, Koizumi H, Kamigaki K, Aoyagi T, Miura Y: Two forms of adenosine deaminase in pig epidermis. J Dermatol 1981, 8:91-95.
41. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M: Nomenclature and classification of purinoceptors. Pharmacol Rev 1994, 46:143-156.
42. Olah ME, Stiles GL: Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995, 35:581-606.
43. Dunwiddie TV, Masino SA: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24:31-55.
44. Palmer TM, Stiles GL: Adenosine receptors. Neuropharmacology 1995, 34:683-694.
45. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortes A, Canela EI, Lopez-Gimenez JF, Milligan G, Lluis C, Cunha RA, Ferre S, Franco R: Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006, 26:2080-2087.
46. El-Ansary A, Ben Bacha A, Al-Ayahdi LY: Relationship between chronic lead toxicity and plasma neurotransmitters in Saudi autistic children. Clin Biochem 2011, 44(13):1116-1120.
47. Studer FE, Fedele DE, Marowsky A, Schwerdel C, Wernli K, Vogt K, Fritschy JM, Boison D: Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006, 142:125-137.
48. Hasko G, Pacher P, Vizi ES, Illes P: Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 2005, 26:511-516.
49. Stubbs G, Litt M, Lis E, Jackson R, Voth W, Lindberg A, litt R: Adenosine Deaminase activity decreased in autism. J Am Acad Child Psychiatry 1982, 21:71-74.
50. El-Ansary AK, Ben Bacha AG, Al-Ayadhi LY: Pro-inflammatory and proapoptotic markers in relation to mono and dications in plasma from autistic patients from Saudi Arabia. J Neuroinflammation 2011, 8:142.
51. El-Ansary A, Al-Daihan S, Al-Dbass A, Al-Ayadhi L: Measurement of selected ions related to oxidative stress and energy metabolism in Saudi autistic children. Clin Biochem 2010, 43(1-2):63-70.
52. Zimmermann H: 5'-Nucleotidase: molecular structure and functional aspects. Biochem J 1992, 285:345-365.
53. Page T, Yu A, Fontanesi J, Nyhan WL: Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci 1997, 94:11601-11606.
54. Page T: Metabolic approaches to the treatment of autism spectrum disorders. J Autism Dev Disord 2000, 30:463-469.
55. Dhossche DM, Rout U: Are autistic and catatonic regression related? A few working hypotheses involving gaba, Purkinje cell survival, neurogenesis, and ECT. Int Rev Neurobiol 2006, 72:55-79.
56. Schmitz C, Van Kooten IA, Hof PR, Van Engeland H, Patterson PH, Steinbusch HW: Autism: neuropathology, alterations of the GABAergic system, and animal models. Int Rev Neurobiol 2005, 71:1-26.
57. McDougle CJ, Erickson CA, Stigler KA, Posey DJ: Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005, 10:9-18.
58. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S: An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001, 62:530-534.
59. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Lazarow A, Nissim I: Brain amino acid requirements and toxicity: the example of leucine. J Nutr 2005, 135:1531-1538.
60. Tapiero H, Mathé G, Couvreur P, Tew KD: Free amino acids in human health and pathologies II. Glutamine and glutamate. Biomed Pharmacother 2002, 56:446-457.